Our Early-Stage Compounds​

Exelixis has a diverse portfolio of small molecule and biologics programs moving forward, covering a broad range of targets and therapeutic modalities. We are committed to further enhancing our early-stage pipeline and expanding our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians.

Program Name
Mechanism
Phase
  • Discovery/
    Preclinical
  • IND
  • Phase 1a
  • Phase 1b
  • Phase 2/3
XL092
Next-generation TKI targeting MET/
VEGFR/AXL/MER
Next-generation TKI targeting MET/
VEGFR/AXL/MER
  • Phase 1b
XL102
Potent, selective, orally bioavailable CDK7 inhibitor
Potent, selective, orally bioavailable CDK7 inhibitor
  • Phase 1a
XB002
Next-generation
tissue factor-targeting ADC
Next-generation
tissue factor-targeting ADC
  • Phase 1a
XL114
CBM pathway inhibitor
CBM pathway inhibitor
  • Discovery/
    Preclinical
Aurigene Collaboration Programs
Undisclosed
Undisclosed
  • Discovery/
    Preclinical
StemSynergy Collaboration Program
CK1α activators
CK1α activators
  • Discovery/
    Preclinical
StemSynergy Collaboration Program
Selective notch inhibitors
Selective notch inhibitors
  • Discovery/
    Preclinical
STORM Therapeutics Collaboration Program
ADAR1
ADAR1
  • Discovery/
    Preclinical
STORM Therapeutics Collaboration Program
Undisclosed
Undisclosed
  • Discovery/
    Preclinical
Exelixis Discovery Programs
Undisclosed
Undisclosed
  • Discovery/
    Preclinical
Biologics Programs Invenra, NBE Therapeutics, Catalent, Gamamabs (AMRII) & Adagene Collaborations
Undisclosed
Undisclosed
  • Discovery/
    Preclinical
  • TKI = tyrosine kinase inhibitor
  • CDK7 = cyclin-dependent kinase 7
  • ADC = antibody-drug conjugate
  • CBM = CARD11-BCL10-MALT1
  • CK1α = casein kinase 1 alpha
  • IND = Investigational New Drug application

Cabozantinib Pipeline

Explore the diverse development program for our flagship molecule